Serratio peptidase
Reading File
Serratiopeptidase is a proteolytic enzyme derived from Serratia marcescens bacteria, used clinically as an anti-inflammatory, anti-edematous, and fibrinolytic agent. Now searching the medical library for detailed textbook coverage.
Searching sources...
Finding Sources
Searching PubMed
serratiopeptidase clinical efficacy
Finding Sources
Searching PubMed
serratiopeptidase enzyme anti-inflammatory
Searching the Web
serratiopeptidase pharmacology mechanism of action clinical uses
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC9599151
Reading Article
PMID: 36291677
Here is a detailed overview of Serratiopeptidase (also called Serrapeptase):
Serratiopeptidase
Source and Nature
- A zinc-containing metalloprotease (serine protease), molecular weight 45-60 kDa, EC number 3.4.24.40
- Belongs to the Serralysin group
- Originally isolated from Serratia marcescens bacteria found in the intestine of the silkworm Bombyx mori
- Now produced commercially from bacterial fermentation
Mechanism of Action
1. Proteolytic/Anti-inflammatory action
- Breaks down non-living proteins (fibrin, dead tissue, inflammatory exudate)
- Acts on peptide bonds between Arg-Gly, Tyr-Tyr, His-Leu, Gly-Ala, and several others
- Has strong affinity for COX-I and COX-II, thereby reducing production of prostaglandins, thromboxanes, and interleukins
- Reduces bradykinin release (a key pain mediator), explaining its analgesic effect
- Decreases vascular permeability and edema fluid by proteolysis of inflammatory proteins
2. Mucolytic action
- Thins mucus secretions by degrading the mucoprotein network
- Enhances expectoration in respiratory conditions
3. Fibrinolytic action
- Degrades fibrin clots and fibrinous deposits
- Helps dissolve atherosclerotic plaques and venous thrombi (experimental evidence)
4. Anti-biofilm action
- Disrupts bacterial biofilms on tissues and medical devices
- This property is independent of its proteolytic activity (a non-proteolytic mechanism)
- Enhances antibiotic penetration and efficacy (synergistic effect)
5. Enhanced antibiotic penetration
- Promotes penetration of antibiotics and chemotherapeutic agents into infected tissues
Pharmacokinetics
- Given orally as enteric-coated tablets (to protect from gastric acid destruction)
- Must be taken on an empty stomach or 30 minutes before food
- Absorbed intact through the intestinal wall via transcytosis
- Distributed to sites of inflammation via blood and lymphatics
Clinical Indications
| Area | Uses |
|---|---|
| Post-surgical/trauma | Reduction of edema and swelling after surgery, dental extraction, molar surgery |
| ENT | Sinusitis, rhinitis, otitis, bronchitis (mucolytic) |
| Respiratory | Bronchial asthma, COPD, COVID-19 (mucolytic + anti-inflammatory) |
| Musculoskeletal | Carpal tunnel syndrome, osteoarthritis, knee pain, joint infections |
| Dentistry | Post-extraction swelling, trismus, pain management |
| Gynaecology | Fibrocystic breast disease, pelvic inflammatory disease |
| Urology | Epididymitis, cystitis |
| Vascular | Chronic venous insufficiency, venous inflammatory disease |
| Infectious | Post-operative infections (synergy with antibiotics) |
| Neurology (experimental) | Alzheimer's disease - degrades amyloid plaques (animal models only) |
Dose
- Standard oral dose: 5-10 mg (equivalent to 10,000-20,000 IU) given 2-3 times daily, on an empty stomach
- Available as enteric-coated tablets (most common) and in sustained-release formulations
- Combination products: paired with diclofenac, trypsin-bromelain-rutoside, or antibiotics
Comparisons with Other Agents
- In acute inflammation, serratiopeptidase showed superior anti-inflammatory action compared to aspirin, trypsin, and chymotrypsin (carrageenan paw edema model)
- For analgesic effect: weaker than betamethasone and ibuprofen
- For edema/trismus management: comparable to methylprednisolone
- For wound management: combination of trypsin + chymotrypsin showed higher efficacy than serratiopeptidase alone in one study
- Seaprose S showed slightly higher efficacy (85% vs 65%) in venous inflammatory disease
Adverse Effects
Generally well-tolerated. Reported adverse effects:
- Mild gastrointestinal disturbance (nausea, diarrhea) - rare
- Stevens-Johnson syndrome (rare, serious)
- Buccal space abscess (case report)
- Potential adverse effects on joint cartilage at high doses (animal data)
- May be dose-dependent or combination-drug related
Emerging Applications
- Cancer therapy: In vitro cytotoxic activity against colon cancer (Caco-2 cells); nanoparticle co-delivery with curcumin shows enhanced anti-cancer activity against HeLa and MCF-7 cells
- COVID-19: Used as a mucolytic agent in respiratory syndrome management
- Biofilm disruption on medical implants
- Nanoparticle-based drug delivery systems for targeted therapy
Key Advantages Over NSAIDs
- Cheaper and safer alternative to NSAIDs
- Does not cause gastric ulceration or inhibit platelet aggregation
- Suitable for long-term use in chronic inflammatory conditions
Key references:
- Nair & Devi, Biomolecules 2022 - comprehensive multifaceted review (PMID: 36291677)
- Serratiopeptidase: Insights into therapeutic applications, PMC 2020 - detailed mechanisms and clinical data
- Hosseini et al., Arch Microbiol 2024 - biobetter derivatives and metalloprotease applications (PMID: 38502196)
Thiocolcicoside
Thiocolchicoside is a muscle relaxant derived from colchicine, acting as a GABA-A receptor modulator and glycine receptor antagonist. It's used for painful muscle spasms and contractures. Let me search for detailed textbook and literature coverage.
Searching sources...
Finding Sources
Searching PubMed
thiocolchicoside muscle relaxant pharmacology
Searching the Web
thiocolchicoside pharmacology mechanism of action indications dose adverse effects
Reading Article
PMID: 42367456
Reading Web Page
https://www.ema.europa.eu/en/news/european-medicines-agency-…
Here is a detailed overview of Thiocolchicoside:
Thiocolchicoside
Source and Nature
- A semi-synthetic derivative of colchicoside, a natural glucoside obtained from the seeds of Gloriosa superba (also sometimes cited from Colchicum autumnale)
- Structurally related to colchicine but has a distinct pharmacological profile
- Brand names: Muscoril, Myoril, Neoflax
- Classification: Centrally acting skeletal muscle relaxant
Mechanism of Action
The exact mechanism is not fully established, but the following are proposed:
| Receptor | Effect |
|---|---|
| GABA-A receptor | Competitive antagonist (paradoxically promotes muscle relaxation via modulation of inhibitory tone; some sources suggest partial agonism/potentiation) |
| Glycine receptor | Competitive antagonist - inhibits inhibitory glycinergic transmission |
| Nicotinic acetylcholine receptors (nAChR) | Antagonism - believed to be the primary mechanism for muscle relaxation |
Key points:
- Acts on inhibitory neurotransmitter pathways at spinal cord and supraspinal levels
- Achieves muscle relaxation without significant sedation (unlike benzodiazepines), attributed to its lack of strong GABA-A potentiation
- Due to glycine and GABA-A receptor antagonism, it has convulsant potential - must be avoided in seizure-prone individuals
Pharmacokinetics
| Parameter | Detail |
|---|---|
| Absorption | Rapid oral absorption; also available IM |
| Metabolism | Hepatic; key metabolite: 3-demethylthiocolchicine (M2 / SL59.0955) |
| M2 metabolite | Associated with aneuploidy (abnormal chromosome numbers) in dividing cells - the basis of genotoxicity concerns |
| Excretion | Renal |
Indications (Post-EMA Restriction)
Following European Medicines Agency (EMA/CHMP) review, use is now restricted to:
- Add-on treatment for painful muscle contractures associated with spinal column disorders (e.g., acute low back pain, cervical pain, torticollis, lumbar/cervical spondylosis)
- Indicated in adults and adolescents ≥16 years only
Previously used (broader) indications included:
- Spasticity (neurological - MS, cerebral palsy, paraplegia)
- Post-surgical muscle spasm
- Sports injuries
- Osteoarthritis-associated muscle spasm
Dose
| Route | Dose | Maximum Duration |
|---|---|---|
| Oral | 8 mg twice daily (some guidelines: 4-8 mg TID) | ≤7 days |
| Intramuscular (IM) | 4 mg every 12 hours | ≤5 days |
| Topical (gel/cream) | Apply 2-3 times daily | Not restricted by EMA |
Topical preparations are not subject to EMA dose/duration restrictions as systemic absorption is minimal.
Adverse Effects
Common:
- Nausea, diarrhea, GI disturbance
- Dizziness (though less sedating than other muscle relaxants)
- Vasovagal reactions (especially with IM injection)
- Allergic reactions (including immediate hypersensitivity - confirmed by skin testing and basophil activation test)
Serious (recorded in pharmacovigilance databases):
- Seizures / convulsions (due to convulsant activity)
- Liver injury (hepatotoxicity)
- Pancreatitis
- Blood cell disorders (myelosuppression)
- Severe cutaneous reactions (Stevens-Johnson syndrome-like)
- Rhabdomyolysis
- Reproductive toxicity: Altered spermatogenesis, azoospermia (male infertility)
- Teratogenicity: Animal studies show teratogenic potential via M2 metabolite-induced aneuploidy
Contraindications
- Pregnancy and lactation (teratogenic - absolute contraindication)
- Women of childbearing potential not using contraception
- Children under 16 years
- Epilepsy / seizure disorders (convulsant potential)
- Chronic/long-term use - not approved for this
- Hypersensitivity to thiocolchicoside or colchicine derivatives
Safety Concerns - EMA Regulatory Action
The EMA CHMP reviewed evidence showing:
- The metabolite M2 (3-demethylthiocolchicine) causes aneuploidy (abnormal chromosome number, loss of heterozygosity) at levels not much above therapeutic doses
- Aneuploidy is a risk factor for:
- Teratogenicity and embryotoxicity
- Spontaneous abortion
- Impaired male fertility
- Theoretically increased cancer risk (with long-term exposure)
- M2 was NOT associated with mutagenicity or clastogenicity (structural chromosome damage)
Result: EMA restricted indications, dose, and duration; contraindicated in pregnancy and children.
Drug Interactions
- CNS depressants / alcohol: Additive CNS depression risk
- Other convulsant agents: Additive seizure risk
- Colchicine: Structural similarity - caution regarding cumulative toxicity
Comparison with Other Muscle Relaxants
| Feature | Thiocolchicoside | Baclofen | Diazepam | Tizanidine |
|---|---|---|---|---|
| Sedation | Low | Moderate | High | Moderate |
| Convulsant risk | Yes | No | No (anticonvulsant) | No |
| Mechanism | GABA-A/Gly antagonist + nAChR | GABA-B agonist | GABA-A positive modulator | α2 agonist |
| Duration limit | ≤7 days oral | Long-term OK | Short-term preferred | As needed |
| Teratogenic concern | Yes (M2 metabolite) | Category C | Category D | Unknown |
Emerging Research (2026)
- Anticancer potential: In vitro MTT assay studies show cytotoxic activity against cancer cell lines (Devi & Khanwelkar, Cureus 2026, PMID: 42333324)
- Antimicrobial activity: Preclinical studies suggest potential in infectious disease management
- Novel drug delivery: Nanogel-based formulations under investigation to improve bioavailability and reduce systemic toxicity
- Fracture healing: Comparative animal studies evaluating effect on bone healing vs. NSAIDs (Bulum et al., 2026, PMID: 41795074)
- Comprehensive 2026 review: Devi et al., Cureus 2026 covers pharmacological, therapeutic, and toxicological profile in depth
Key Takeaway
Thiocolchicoside is a useful short-term muscle relaxant for spinal pain-related contractures, with the advantage of low sedation. However, its genotoxic metabolite (M2), teratogenicity, convulsant potential, and reproductive toxicity impose strict limits on its use - short treatment courses only, not in pregnancy, not in children, and with caution in seizure-prone patients. The EMA has significantly narrowed its approved indications for systemic use.
This is a shared conversation. Sign in to Orris to start your own chat.